The report offers new insights into the limits of the BCL2 inhibitor among patients who have myelodysplastic syndromes. A new report explains why patients with myelodysplastic syndromes (MDS) become ...

Distinguishing myelodysplastic syndrome (MDS) from acute myeloid leukemia (AML) solely on the basis of a 20% bone marrow blast cutoff ignores important patient characteristics and genetic factors that ...

Researchers at Moffitt Cancer Center and colleagues at six other institutions have recently tested a treatment for patients with myelodysplastic syndrome, or MDS, a blood-related malignancy that ...

An expert explained the burden that red blood cell transfusions can place on patients with MDS. Among patients with myelodysplastic syndromes (MDS), treatment with Reblozyl (luspatercept) resulted in ...

Patients with histories of inflammatory bowel disease and systemic lupus erythematosus were also at elevated risks of myelodysplastic syndromes (MDS), the authors found. A new report shows that ...

Myelodysplastic syndromes (MDS) are a group of blood cancers that affect the bone marrow and can result in a low levels of blood cells. When MDS affects red blood cells, it can lead to anemia in some ...

Myelodysplastic syndromes (MDS) are blood cancers caused by an insufficient production of healthy blood cells. Production of irregular cells leads to anemia, where the body’s organs and tissues don’t ...